Treatment Of Autoimmune Disease By Modulating Annexin-1 (Lipocortin 1)

Abstract

The present invention provides a specific binding molecule which binds to Annexin-1 (Anx-A1) for use in the treatment of T cell-mediated disease

1 - 12 . (canceled) 
     
     
         13 . A method of treating a T cell-mediated disease in an animal comprising administering to the animal in need thereof a therapeutic amount of an antibody, or fragment thereof, that binds to Annexin-1 (Anx-A1). 
     
     
         14 . The method of  claim 13  wherein the antibody binds to an N-terminal peptide of Anx-A1 of at least 50 amino acid residues. 
     
     
         15 . The method of  claim 13  wherein the antibody binds to the N-terminal peptide Ac.2-26 of Anx-A1. 
     
     
         16 . The method of  claim 13  wherein the antibody binds to a fragment of at least 6 amino acids of the N-terminal peptide Ac.2-26 of Anx-A1. 
     
     
         17 . The method of  claim 13  wherein the antibody is a monoclonal antibody. 
     
     
         18 . The method of  claim 13  wherein the antibody fragment is chosen from Fab fragment, F(ab′) 2  fragment, Fv fragment, and single chain Fv (scFv) molecule. 
     
     
         19 . The method of  claim 13  wherein the antibody is a chimeric antibody. 
     
     
         20 . The method of  claim 13  wherein the antibody is a humanized antibody. 
     
     
         21 . The method of  claim 13  wherein the T cell-mediated disease is chosen from graft-versus-host disease, graft rejection, atherosclerosis, HIV, AIDS, psoriasis, and an autoimmune disease. 
     
     
         22 . The method of  claim 13  wherein the T cell-mediated disease is chosen from atherosclerosis, HIV, AIDS, and psoriasis. 
     
     
         23 . The method of  claim 21  wherein the autoimmune disease is chosen from rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Addison's disease, Grave's disease, scleroderma, polymyositis, diabetes mellitus, autoimmune uveoretinitis, ulcerative colitis, pemphigus vulgaris, inflammatory bowel disease, and autoimmune thyroiditis. 
     
     
         24 . The method of  claim 21  wherein the autoimmune disease is chosen from rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. 
     
     
         25 . A pharmaceutical composition comprising a specific binding molecule which binds to Annexin-1 (Anx-A1).